4R-tauopathies are a group of neurodegenerative disorders characterized by the abnormal accumulation of tau protein isoforms containing four microtubule-binding repeats. While all involve tau pathology, these diseases show distinct clinical phenotypes and regional vulnerabilities driven by differential cell-type involvement. This page provides a comprehensive comparison of cell-type vulnerability patterns across Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism-17 (FTDP-17).
Understanding which cell types are affected in each disease provides critical insights into disease mechanisms, explains the diverse clinical presentations, and informs therapeutic targeting strategies.
| Cell Type | PSP | CBD | AGD | GGT | FTDP-17 |
|-----------|-----|-----|-----|-----|---------|
| Cortical Pyramidal Neurons | ++ | +++ | ++ | +++ | +++ |
| Substantia Nigra DA Neurons | ++ | ++ | + | + | +++ |
| Cholinergic (PPN/LDT) | +++ | ++ | + | + | ++ |
| GABAergic Interneurons | ++ | +++ | ++ | + | ++ |
| Dopaminergic Neurons | ++ | ++ | + | + | +++ |
| Tufted Astrocytes | +++ | - | - | - | - |
| Astrocytic Plaques | - | +++ | - | ++ | - |
| Coiled Bodies (Oligodendrocytes) | ++ | ++ | +++ | +++ | ++ |
| Globular Oligodendroglial Inclusions | - | - | - | +++ | - |
| Microglia | ++ | ++ | + | ++ | ++ |
Legend: - absent/minimal, + mild, ++ moderate, +++ severe
PSP demonstrates a characteristic pattern of neuronal loss affecting multiple brainstem and subcortical structures, with prominent glial involvement.
Neuronal Vulnerability:
- Brainstem nuclei: The pedunculopontine nucleus (PPN) and laterodorsal tegmental nucleus show significant degeneration, contributing to the characteristic supranuclear gaze palsy and sleep disturbances.
- Substantia nigra: Dopaminergic neuron loss in the substantia nigra pars compacta contributes to the overlap of parkinsonian motor symptoms.
- Subthalamic nucleus: Severe degeneration of STN neurons is a hallmark, correlating with postural instability and falls.
- Red nucleus: Involved in oculomotor control pathways.
- GABAergic neurons: Striatal and brainstem GABAergic populations exhibit early loss, correlating with akinesia and axial rigidity.
Glial Vulnerability:
- Tufted astrocytes: PSP is distinguished by tau-positive astrocytes with dense perisomatic and proximal process inclusions, producing the classic tufted appearance. These are prominent in motor and premotor circuits including subthalamic nucleus, globus pallidus, substantia nigra, and brainstem structures.
- Coiled bodies: Oligodendroglial inclusions present in white matter tracts.
- Nigral microglia: Show activation patterns associated with neuroinflammation.
CBD exhibits cortical and subcortical involvement with pronounced asymmetry, reflecting its characteristic clinical presentation.
Neuronal Vulnerability:
- Cortical pyramidal neurons: Layer III/V pyramidal neurons in motor and premotor cortices show tau pathology and degeneration, correlating with apraxia and cortical sensory loss.
- Ballooned (achromatic) neurons: Swollen, eosinophilic neurons with reduced staining — a hallmark neuropathological feature of CBD.
- Basal forebrain cholinergic neurons: Early involvement contributes to cognitive decline and cortical atrophy patterns.
- GABAergic interneurons: Parvalbumin (PV) and somatostatin-positive interneurons demonstrate significant pathology, affecting cortical inhibition.
Glial Vulnerability:
- Astrocytic plaques: CBD shows a different astroglial morphology from PSP — ring-like tau-positive distal processes with relative sparing of the soma, usually in cortex and subcortical white matter.
- Coiled bodies: Present in both gray and white matter.
- Microglia: Activated in affected regions contributing to neuroinflammation.
Asymmetry: A key feature of CBD is the marked asymmetry of neurodegeneration, with one hemisphere significantly more affected than the other.
AGD is characterized by argyrophilic grains in neuronal dendrites with prominent limbic system involvement.
Neuronal Vulnerability:
- Limbic structures: The amygdala, hippocampus, and entorhinal cortex show earliest involvement.
- Entorhinal cortex neurons: Early and severe involvement of Layer II entorhinal neurons is a hallmark.
- Anterior cingulate: Involved in Stage II/III disease.
- Temporal pole neurons: Affected in later stages.
Glial Vulnerability:
- Coiled bodies: Prominent oligodendroglial inclusions in white matter, particularly in limbic regions.
- Pretangles in neurons: Extensive pretangle formation before mature neurofibrillary tangle development.
- Astrocytes: Show reactive changes but lack the distinctive morphology seen in PSP and CBD.
Staging (Saito Classification):
- Stage I: Amygdala, entorhinal cortex
- Stage II: Hippocampus, anterior cingulate
- Stage III: Broader limbic, anterior temporal
- Stage IV: Orbitofrontal, insular cortex
GGT is defined by distinctive globular inclusions in glial cells, setting it apart from other 4R tauopathies.
Neuronal Vulnerability:
GGT shows variable neuronal involvement depending on subtype:
- Type I (Frontotemporal): Cortical neurons in frontal and temporal regions
- Type II (Motor): Motor cortex and corticospinal tract neurons
- Type III (Combined): Both frontotemporal and motor system involvement
Glial Vulnerability — The Hallmark Feature:
- Globular Oligodendroglial Inclusions (GOIs): Round to oval, well-circumscribed cytoplasmic inclusions in oligodendrocytes. Distinguished from coiled bodies by larger size, spherical shape, and displacement of nucleus to cell periphery.
- Globular Astroglial Inclusions (GAIs): Present in astrocytic populations, particularly prominent in Type II and III.
- White matter predominance: GOIs are located predominantly in white matter along myelinated fiber tracts.
The three GGT subtypes show different patterns:
- Type I: Predominant GOIs, less motor involvement
- Type II: Both GOIs and GAIs prominent, severe corticospinal tract degeneration
- Type III: Most extensive pathology across cortical, subcortical, and spinal regions
FTDP-17 is caused by MAPT mutations and shows variable phenotypes based on the specific mutation.
Neuronal Vulnerability:
- Frontotemporal cortical neurons: Severe loss in frontal and temporal cortices, correlating with behavioral changes and cognitive decline.
- Substantia nigra dopamine neurons: Significant loss contributing to parkinsonian features.
- Pyramidal neurons: Layer-specific degeneration in motor cortex in cases with corticospinal involvement.
- Hippocampal neurons: Variable involvement depending on mutation.
Glial Vulnerability:
- Oligodendrocytes: Variable coiled body formation.
- Astrocytes: Reactive gliosis in affected regions.
- Microglia: Activated in areas of neurodegeneration.
The selective vulnerability in 4R-tauopathies relates to differential expression of tau isoforms across cell types:
- 4R tau predominance: All five diseases show accumulation of 4R tau, but the cellular distribution varies
- Alternative splicing: Cell-type-specific regulation of MAPT exon 10 splicing influences vulnerability
- Tau post-translational modifications: Differential phosphorylation patterns across cell types
- Neuronal connectivity: Neurons with extensive axonal projections show increased vulnerability to tau pathology
- Metabolic demands: High-energy requirement neurons are more susceptible
- Calcium handling: Differences in calcium homeostasis affect vulnerability
- Proteostasis failure: Astrocytes and oligodendrocytes show different capacities for handling tau aggregates
- Inflammatory signaling: Microglial activation states vary across diseases
- Metabolic coupling: Astrocyte-neuron metabolic coupling disruption contributes to selective vulnerability
Recent cryo-electron microscopy studies have revealed distinct tau filament structures in different 4R-tauopathies:
- CBD fold: Distinct helical filament architecture different from AD and PSP
- PSP fold: Globose NFT pattern characteristic of PSP
- AGD grains: spindle-shaped argyrophilic grains
These structural differences (tau strains) may drive selective vulnerability to different clinical syndromes.
| Disease |
Primary Cell Vulnerability |
Key Clinical Features |
| PSP |
Brainstem nuclei, tufted astrocytes |
Vertical gaze palsy, postural instability, falls |
| CBD |
Cortical pyramidal, astrocytic plaques |
Apraxia, alien limb, asymmetric rigidity |
| AGD |
Limbic neurons, coiled bodies |
Memory impairment, emotional changes |
| GGT |
Globular glial inclusions |
FTD phenotypes, motor neuron disease |
| FTDP-17 |
Cortical neurons, substantia nigra |
Dementia, parkinsonism, behavior changes |
Understanding cell-type vulnerability has direct implications for therapeutic development:
- Cell-specific targeting: Different diseases may require targeting different cell types
- Astrocyte-directed therapies: PSP tufted astrocytes vs. CBD astrocytic plaques may require different approaches
- Oligodendrocyte protection: GGTs prominent GOIs suggest oligodendrocyte-directed strategies
- Microglial modulation: Common neuroinflammatory mechanisms across diseases
- Tau strain-specific approaches: Different filament structures may require different aggregation inhibitors